Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selonsertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 known ✓ | Q99683 | 20/20 | 0.89 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selonsertib SCHEMBL30714545 | 0.97 | MAP3K5 (0.90) | MAP3K5MAP3K6 | |
| Selonsertib SCHEMBL17873177 | 0.96 | MAP3K5 (0.94) | MAP3K5MAP3K6 | |
| Selonsertib SCHEMBL17873147 | 0.96 | MAP3K5 (0.94) | MAP3K5MAP3K6 | |
| Selonsertib SCHEMBL29977277 | 0.94 | MAP3K5 (1.00) | MAP3K5MAP3K6 | |
| Selonsertib SCHEMBL14672984 | 0.94 | MAP3K5 (1.00) | MAP3K5MAP3K6 | |
| Selonsertib SCHEMBL17873132 | 0.94 | MAP3K5 (0.98) | MAP3K5MAP3K6 | |
| Selonsertib SCHEMBL17873174 | 0.92 | MAP3K5 (0.96) | MAP3K5MAP3K6 | |
| Selonsertib SCHEMBL17873192 | 0.92 | MAP3K5 (0.87) | MAP3K5MAP3K6 | |
| Selonsertib SCHEMBL17873149 | 0.92 | MAP3K5 (0.92) | MAP3K5MAP3K6 | |
| Selonsertib SCHEMBL17873198 | 0.92 | MAP3K5 (0.92) | MAP3K5MAP3K6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4265250-A2 | SOLID FORMS OF AN ASK1 INHIBITOR | Gilead Sciences, Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| EP-4265250-A2 | SOLID FORMS OF AN ASK1 INHIBITOR | Gilead Sciences, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-10946004-B2 | Solid forms of an ASK1 inhibitor | GILEAD SCIENCES, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200061042-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | GILEAD SCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20180243281-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | GILEAD SCIENCES, INC. | 2018-08-30 | — | — | US | disclosed |
| US-9907790-B2 | Solid forms of an ASK1 inhibitor | GILEAD SCIENCES, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3237402-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170209423-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9643956-B2 | Solid forms of an ASK1 inhibitor | GILEAD SCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160280683-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | GILEAD SCIENCES, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2016105453-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | GILEAD SCIENCES, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946004-B2 | Solid forms of an ASK1 inhibitor | MARK1, MAP3K1, MAP3K19 | MAP3K5 7/4885MAP3K6 16/4885 |
| US-20160280683-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | MARK1, MAP3K1, MAP3K19 | MAP3K5 7/4885MAP3K6 16/4885 |
| US-20170209423-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | MARK1, MAP3K1, MAP3K19 | MAP3K5 7/4885MAP3K6 16/4885 |
| US-20180243281-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | MARK1, MAP3K1, MAP3K19 | MAP3K5 7/4885MAP3K6 16/4885 |
| US-20200061042-A1 | SOLID FORMS OF AN ASK1 INHIBITOR | MARK1, MAP3K1, MAP3K19 | MAP3K5 7/4885MAP3K6 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.